Alexander Roth
Overview
Explore the profile of Alexander Roth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
177
Citations
19670
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tometten M, Beier F, Kirschner M, Schumacher Y, Walter J, Vieri M, et al.
Blood Adv
. 2025 Feb;
PMID: 39938003
Pathogenic germline variants affecting proper telomere maintenance result in premature telomere shortening and cause telomere biology disorders (TBDs). While classical dyskeratosis congenita in children is rather well defined, late-onset ("cryptic")...
2.
Kennedy B, Noftall E, Dean C, Roth A, Clark K, Rowles D, et al.
Front Immunol
. 2025 Jan;
15:1512543.
PMID: 39872527
Introduction: Hyperthermia is an established adjunct in multimodal cancer treatments, with mechanisms including cell death, immune modulation, and vascular changes. Traditional hyperthermia applications are resource-intensive and often associated with patient...
3.
Kulasekararaj A, Brodsky R, Schrezenmeier H, Griffin M, Roth A, Piatek C, et al.
Ann Hematol
. 2025 Jan;
104(1):81-94.
PMID: 39841198
Ravulizumab is a second-generation complement component 5 (C5) inhibitor (C5i) approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) following positive results from two pivotal trials in patients with PNH...
4.
Cosson V, Fu R, Kulasekararaj A, Nishimura J, Panse J, Roth A, et al.
Br J Clin Pharmacol
. 2025 Jan;
PMID: 39835421
Aims: Crovalimab is a novel C5 inhibitor administered first intravenously and then subcutaneously in patients with paroxysmal nocturnal haemoglobinuria (PNH) naive to complement inhibition or switching from eculizumab or ravulizumab....
5.
Dingli D, De Castro Iii C, Koprivnikar J, Kulasekararaj A, Maciejewski J, Mulherin B, et al.
Hematology
. 2024 Dec;
29(1):2329030.
PMID: 39665683
Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, non-malignant hematologic disease characterized by complement-mediated hemolysis (with or without hemoglobinuria), fatigue, increased susceptibility to thrombosis, and bone marrow dysfunction. The...
6.
Roth A, Kulasekararaj A, Scheinberg P, Nishimura J
Immunotherapy
. 2024 Dec;
16(20-22):1185-1196.
PMID: 39620653
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, rare, life-threatening hematopoietic stem cell disorder that causes stem cell-derived cells to be vulnerable to complement-mediated lysis and manifests as hemolytic anemia, thrombosis,...
7.
Roth A, Fu R, He G, Alzahrani H, Chou S, Hicheri Y, et al.
Eur J Haematol
. 2024 Nov;
114(2):373-382.
PMID: 39535306
Objectives: To evaluate the tolerability of crovalimab versus eculizumab in C5 inhibitor (C5i)-naive and -experienced patients with PNH from COMMODORE 2, 3 and 1 (NCT04434092, NCT04654468 and NCT04432584). Methods: Pooled...
8.
Grant J, Wang Y, Roth A, Liu Y, Rahimi R, Song G, et al.
ACS Appl Mater Interfaces
. 2024 Oct;
16(44):60749-60761.
PMID: 39449496
Highly anisotropic piezoelectric composites promise to progress electroacoustic devices as a class by combining the advantages of both piezoceramics and polymers. Fundamentally, piezoelectric loudspeakers employ the converse piezoelectric effect to...
9.
Jevnikar B, Huffman N, Roth A, Klika A, Deren M, Zhang C, et al.
Knee
. 2024 Sep;
51:74-83.
PMID: 39241673
Background: Community deprivation has been linked to poor health outcomes following primary total knee arthroplasty (pTKA), but few studies have explored revision TKA (rTKA). The present study analyzed implications of...
10.
Roth A, Broome C, Barcellini W, Jilma B, Hill Q, Cella D, et al.
EClinicalMedicine
. 2024 Aug;
74:102732.
PMID: 39114274
Background: Cold agglutinin disease (CAD) is a rare subtype of autoimmune haemolytic anaemia characterised by classical complement pathway-mediated haemolysis, fatigue, and poor quality of life (QoL). Sutimlimab, a C1s inhibitor,...